Godavari Drugs Ltd
Godavari Drugs Ltd (GODAVARI) last reported results for the quarter ended Jun 2026, with sales of ₹27.96 crore and net profit of ₹1.11 crore. The stock last traded at ₹117, a market capitalisation of ₹128 crore, on a P/E of 32.8. Over the past 52 weeks the stock has ranged between ₹69.7 and ₹135. Figures are as of 6 Oct 2026 and are not real time.
Godavari Drugs Ltd share price and key metrics
- Current price
- ₹117
- Market cap
- ₹128 cr
- Stock P/E
- 32.8
- Book value
- ₹74.8
- ROE
- 6.14%
- ROCE
- 6.55%
- Dividend yield
- 0.00%
- 52w high / low
- 135/69.7
Metrics as of 6 Oct 2026. Not real time.
Track Godavari Drugs Ltd
Cruxal reads every Godavari Drugs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Godavari Drugs Ltd growth and returns
- 10 Years
- 4%
- 5 Years
- -3%
- 3 Years
- -13%
- TTM
- 5%
- 10 Years
- 10%
- 5 Years
- -2%
- 3 Years
- 0%
- TTM
- 3%
- 10 Years
- 9%
- 5 Years
- 11%
- 3 Years
- 8%
- 1 Year
- 35%
- 10 Years
- 11%
- 5 Years
- 12%
- 3 Years
- 10%
- Last Year
- 6%
Godavari Drugs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹27.96 cr, up 17.4% from ₹23.81 cr a year earlier. Net profit was ₹1.11 cr, up 6.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 26.09 | 29.55 | 25.5 | 23.81 | 26.65 | 22.18 | 33.16 | 27.96 |
| Expenses | 23.19 | 26.97 | 22.39 | 20.91 | 24.65 | 19.71 | 30.22 | 25.44 |
| Operating profit | 2.9 | 2.58 | 3.11 | 2.9 | 2 | 2.47 | 2.94 | 2.52 |
| OPM % | 11.12% | 8.73% | 12.20% | 12.18% | 7.50% | 11.14% | 8.87% | 9.01% |
| Other income | 0.01 | 0.1 | 0.11 | 0.01 | 0.64 | 0.27 | 0.25 | 0.15 |
| Interest | 1.08 | 1.11 | 1.11 | 1 | 0.91 | 1.11 | 0.96 | 0.9 |
| Depreciation | 0.58 | 0.64 | 0.67 | 0.6 | 0.6 | 0.61 | 0.61 | 0.59 |
| Profit before tax | 1.25 | 0.93 | 1.44 | 1.31 | 1.13 | 1.02 | 1.62 | 1.18 |
| Tax % | 12.80% | 16.13% | 38.19% | 19.85% | 10.62% | 25.49% | 20.37% | 5.93% |
| Net profit | 1.09 | 0.77 | 0.89 | 1.04 | 1 | 0.76 | 1.29 | 1.11 |
| EPS (₹) | 1.45 | 1.02 | 1.18 | 1.38 | 1.33 | 1.01 | 1.27 | 1.10 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Godavari Drugs Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 76 | 64 | 84 | 96 | 123 | 161 | 160 | 157 | 113 | 106 | 110 |
| Operating profit | 5 | 4 | 5 | 6 | 10 | 11 | 10 | 13 | 12 | 10 | 10 |
| OPM % | 7% | 6% | 7% | 6% | 8% | 7% | 6% | 8% | 10% | 10% | 9% |
| Net profit | 2 | 1 | 1 | 2 | 4 | 5 | 4 | 6 | 4 | 4 | 4 |
| EPS (₹) | 2.40 | 1.10 | 1.61 | 2.66 | 5.48 | 6.97 | 5.03 | 7.37 | 5.82 | 4.04 | 4.71 |
TTM is the trailing twelve months to the most recent quarter.
Godavari Drugs Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 |
| Reserves | 9 | 10 | 11 | 13 | 17 | 22 | 26 | 31 | 36 | 66 |
| Borrowings | 16 | 19 | 22 | 28 | 30 | 23 | 36 | 58 | 64 | 82 |
| Other liabilities | 24 | 27 | 33 | 36 | 36 | 49 | 52 | 38 | 35 | 43 |
| Total liabilities | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 143 | 200 |
| Fixed assets | 13 | 15 | 15 | 14 | 22 | 26 | 25 | 27 | 33 | 30 |
| CWIP | 0 | 1 | 2 | 9 | 1 | 0 | 9 | 18 | 30 | 57 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 43 | 47 | 57 | 61 | 68 | 75 | 87 | 90 | 81 | 114 |
| Total assets | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 143 | 200 |
As reported by the company. Total assets equal total liabilities by construction.
Godavari Drugs Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 5 | 4 | 4 | 6 | 1 | 11 | 13 | 18 | 11 | 1 |
| Cash from investing | -3 | -3 | -2 | -7 | -1 | -5 | -9 | -13 | -20 | -26 |
| Cash from financing | -2 | -0 | -1 | 0 | 0 | -6 | -4 | -6 | 8 | 37 |
| Net cash flow | 0 | 1 | -0 | -0 | 0 | 1 | 1 | -0 | -0 | 12 |
| Free cash flow | 1 | 0 | 1 | -1 | -0 | 6 | 4 | 5 | -9 | -26 |
| CFO / operating profit | 108% | 109% | 73% | 108% | 26% | 110% | 143% | 146% | 105% | 19% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Godavari Drugs Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 17% | 11% | 12% | 12% | 18% | 18% | 14% | 14% | 10% | 7% |
| Debtor days | 117 | 152 | 148 | 137 | 134 | 126 | 132 | 138 | 136 | 150 |
| Inventory days | 70 | 100 | 93 | 84 | 55 | 28 | 57 | 62 | 125 | 217 |
| Days payable | 124 | 171 | 171 | 144 | 112 | 121 | 132 | 96 | 128 | 163 |
| Cash conversion cycle | 63 | 81 | 70 | 78 | 78 | 33 | 58 | 105 | 133 | 204 |
| Working capital days | 40 | 47 | 38 | 31 | 46 | 32 | 23 | 9 | 11 | 42 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Godavari Drugs Ltd shareholding pattern
Promoters held 40.23% at Jun 2026, down from 52.63% at Jun 2025. DIIs 2.74%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 52.63% | 52.63% | 52.63% | 52.63% | 52.61% | 52.61% | 40.23% | 40.23% |
| DIIs | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 2.47% | 2.74% |
| Public | 46.87% | 46.87% | 46.87% | 46.87% | 46.90% | 46.89% | 57.31% | 57.04% |
| No. of shareholders | 7,709 | 7,915 | 7,881 | 7,828 | 7,720 | 7,483 | 7,300 | 6,722 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Godavari Drugs Ltd corporate filings
- Godavari Drugs Limited shareholders approve expansion into nutraceuticals and health supplements segmentAGM/EGMhigh impact
Cruxal's analysis: Godavari Drugs Limited has successfully concluded its 38th Annual General Meeting, where…
Read the full analysis - Godavari Drugs Limited Announces Strategic Diversification into Nutraceuticals and Updates on DHDT CommercializationAGM/EGMhigh impact
Cruxal's analysis: Godavari Drugs Limited, during its 38th Annual General Meeting, announced a strategic…
Read the full analysis - Intimation of Closure of Trading Window with effect from 1st October, 2026, for the purpose of consideration and approval of the unaudited Financials for the quarter and half year ended ....Insider Trading / SASTlow impact
- Godavari Drugs Ltd dispatches physical copies of Annual Report for FY 2025-26Company Updatelow impact
Cruxal's analysis: Godavari Drugs Ltd has initiated the dispatch of physical letters to shareholders whose…
Read the full analysis - Godavari Drugs Ltd announces 38th Annual General Meeting and E-Voting detailsCompany Updatelow impact
Cruxal's analysis: Godavari Drugs Ltd has published a newspaper notice regarding its 38th Annual General…
Read the full analysis - Godavari Drugs Limited Announces 38th AGM and Strategic Expansion into NutraceuticalsAGM/EGMmedium impact
Cruxal's analysis: Godavari Drugs Limited has scheduled its 38th Annual General Meeting for September 25…
Read the full analysis - Godavari Drugs Limited announces Book Closure and E-voting schedule for 38th Annual General MeetingCorp. Actionlow impact
Cruxal's analysis: Godavari Drugs Limited has formally notified the BSE of its book closure period from…
Read the full analysis - Godavari Drugs Ltd announces board approval for amendments to Memorandum of AssociationCompany Updatelow impact
Cruxal's analysis: The Board of Directors of Godavari Drugs Ltd has approved amendments to the company's…
Read the full analysis - Godavari Drugs Limited Seeks Shareholder Approval to Diversify into Nutraceuticals and Food Ingredients BusinessOthersmedium impact
Cruxal's analysis: Godavari Drugs Limited has announced a strategic move to expand its business scope by…
Read the full analysis - Godavari Drugs Ltd submits statement on deviation or variation in fund utilization for Q1 FY2027Company Updatelow impact
Cruxal's analysis: Godavari Drugs Ltd has filed its statement regarding the deviation or variation in the…
Read the full analysis - Godavari Drugs Limited reports Q1 FY2027 financial results with net profit of 1.11 croreCompany Updatelow impact
Cruxal's analysis: Godavari Drugs Limited has submitted its unaudited financial results for the quarter…
Read the full analysis - Godavari Drugs Ltd allots 7,86,690 equity shares to promoters at Rs 89 per shareCompany Updatemedium impact
Cruxal's analysis: Godavari Drugs Ltd has approved the allotment of 7,86,690 equity shares to the promoter…
Read the full analysis - Godavari Drugs Limited reports Q1 FY27 results with 17.4% YoY revenue growth but sequential margin compressionResultmedium impact
Cruxal's analysis: Godavari Drugs Limited reported Q1 FY27 revenue from operations of 27.96 crore…
Read the full analysis - Godavari Drugs Limited reports Q1 FY27 results and completes preferential allotment of 7.87 lakh shares to promotersBoard Meetingmedium impact
Cruxal's analysis: Godavari Drugs Limited reported Q1 FY27 revenue from operations of 27.96 crore, down from…
Read the full analysis - Godavari Drugs Limited issues corrigendum to correct board meeting date for Q1 FY2027 financial resultsBoard Meetinglow impact
Cruxal's analysis: Godavari Drugs Limited has issued a formal corrigendum to rectify a typographical error…
Read the full analysis - Godavari Drugs Limited schedules Board Meeting for August 24, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Godavari Drugs Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.